Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Here in Chicago, residents are reeling over the removal of the famed rat hole, a rat-shaped indentation on a piece of sidewalk that drew crowds, fans, and even a proposal and a marriage.
The need-to-know this morning
- AstraZeneca reported first-quarter sales and profits that topped analyst estimates, buoyed by its blockbuster cancer drugs.
- It’s a busy day for pharma earnings: Merck, Sanofi, Daiichi Sankyo, Astellas, and Bristol Myers Squibb.
- Regeneron Pharmaceuticals and Mammoth Biosciences are partnering to develop new CRISPR-based gene therapies.
A hospital takes a gene therapy’s approval into its own hands
What happens if, as an academic, you develop a promising gene therapy, but no company is willing to take it to market? Well, one option is — you do it yourself.
Click this link for the original source of this article.
Author: Elaine Chen
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.